Daguang is the managing director of Yonjin Venture. Before venture investment, Daguang spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, PsychoGenics, EMD Serono and Sanofi.

Daguang received his bachelor degree in biochemistry from Jilin University in China, and his PhD in molecular genetics from the Washington University in St Louis in the US. Daguang conducted postdoctoral research at Stanford University with Professor Roger Kornberg.

Mao is an Investment Manager at Yonjin Venture, specializing in the Medtech industry. Prior to joining Yonjin in 2021, he worked as a neuroimaging physicist. His extensive experience includes various roles at Philips healthcare, Johns Hopkins and National Institute of Health.

Chensu is an Investment Manager at Yonjin Venture, specializing in innovative therapies and medical devices. Previously, she was a Consultant at Boston Consulting Group (BCG), advising global biopharma and medtech firms. Before joining BCG, she served as a Senior Scientist at Pfizer, focusing on immuno-oncology drug discovery.

Chensu holds a PhD in Biomedical Engineering from UT Southwestern Medical Center, with postdoctoral training in immuno-oncology at Massachusetts Institute of Technology, and a BS in Biomedical Engineering from Southeast University, China.